RefleXion’s biology-guided radiotherapy (BgRT) allows us to detect and respond to signals emitted from the cancer itself, and for the first time, use them to guide immediate treatment.
When PET radiotracers are introduced into the body, cancer absorbs them and acts as a biological beacon, which our machine can use to track and treat cancer in real time.
Learn More About Emissions
Our technology aims to deliver high doses of radiation to tumors, even while in motion, for greater impact to the tumor with less dose to the surrounding tissue.
Learn About Targeting
Most patients with stage four cancer are not considered candidates for definitive radiotherapy due to the challenge of treating multiple tumors. Our breakthrough technology is challenging that and aims to treat multiple tumors, in parallel, during a single session.
Discover the Potential
Treatment isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. RefleXion will work together with chemotherapy, immunotherapy and targeted drugs for potentially better outcomes.
Learn About Treatment
By combining PET-CT and radiotherapy, we're able to find and treat cancer using its own emissions.
Discover RefleXion Therapy.
See how RefleXion Therapy can play a role
in your cancer program.
Lungs among most common site for metastatic tumors HAYWARD, Calif., Dec. 1, 2021 – RefleXion Medical, Inc., a therapeutic oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its biology-guided radiotherapy* (BgRT) for use in treating lung tumors. The breakthrough potential of BgRT […]
Physicians at Stanford Radiation Oncology have treated the first patient using the RefleXion X1 system. The RefleXion X1 combines high quality computed tomography (CT) imaging, known as fan-beam CT, with a linear accelerator to reduce motion artifacts that can inhibit accurate targeting of the radiation dose to a patient's tumor. According to the company, its design rotates up to 60 times faster than other linear accelerators and modulates dose delivery from 100 points per beam station.
Roughly one in eight men in the U.S. will be diagnosed with prostate cancer during their lifetime, making it the second most common cancer for men after skin cancer.1 Without using the recently approved molecular imaging method targeting PSMA during the initial staging, misdiagnosis of the correct prostate cancer stage happens in up to 50% […]
Let us tell you more.
Contact UsStay up to date.
Sign Up